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Bouchecareilh et al. deliver a great overview on the molecular 
pathology and the clinical phenotypes of homozygous and 
heterozygous AATD-mediated liver disease. They go into great detail 
on the different isoforms and what they mean for chronic liver disease, 
including risk factors and differential diagnosis with various concurring 
conditions. For many years, hepatologists knew about the condition, but not much 
attention was given to it because of the lack of established treatment options 
beyond liver transplantation once the liver advanced to end-stage liver disease. 
It was not until recently that several new treatment options started to emerge: 
from promoting autophagy using old drugs licensed for very different indications 
(e.g., carbamazepine) to innovative gene silencing (siRNA) or even gene editing 
(CRISPR-Cas) methods currently under clinical or pre-clinical development. These 
are starting to become exciting times for a once neglected chronic liver disease. 
Prof Markus Peck-Radosavljevic
Klinikum Klagenfurt am Wörthersee, Austria
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INTRODUCTION
Alpha-1 antitrypsin deficiency (AATD), described 
in 1963 by Laurell and Eriksson,1 is a rare inherited 
disorder with a prevalence of approximately 1 
in 2,000–5,000 births in North American and 
European populations. AATD is associated 
with lung (emphysema) and/or liver damage 
(cirrhosis). Mutations in SERPINA1 (chromosome 
14), which encodes Alpha-1 antitrypsin 
(AAT) protein, cause AATD, which leads to a 
reduced level of AAT in serum.2,3 The secretion 
rate functionality of AAT depends on the 
inherited mutation.3
Hepatocytes are the major source of AAT 
production in the liver. Around 1.5 g/L of this 
protein is secreted into the bloodstream in 
healthy adults. The main function of AAT is to protect 
the lung from non-specific protease-mediated 
degradation. AAT is carried by blood to the lung 
interstitium and the alveolar lining fluid, where 
it inhibits neutrophil serine proteases, such 
as neutrophil elastase (NE), cathepsin G, and 
proteinase-3. AAT is the main natural antagonist 
of NE. The latter is responsible for elastin 
degradation, the main constituent of the 
alveoli essential for the lung function.4 NE also 
presides over a wide range of pro-inflammatory 
actions potentially leading to several types of 
lung alterations, including emphysema and 
bronchiectasis.5 Thus, a reduced AAT serum 
concentration, as observed in AATD, results 
in lung tissue damage and major respiratory 
diseases, such as emphysema.6
In addition to the lung issues, some AATD 
patients may also develop liver diseases such 
as cirrhosis or hepatocellular carcinoma (HCC). 
AATD is the most common genetic cause of liver 
disease in children.7 Over the past 20 years, there 
has been an increase in the prevalence of the 
adult form of AATD-mediated liver disease. 
More than 88% of patients who undergo liver 
transplantation for AATD are adults, with the peak 
age range being 50–64 years. The adult form 
of the disease seems to be an age-dependent 
degenerative disease. This is in contrast to the 
paediatric form of the disease, the progression 
and severity of which is associated with other 
genetic factors.8
This wide variation in the severity and form 
of liver disease among patients is still not well 
understood, but genetic predisposition could 
play a role.9,10 However, the genetic underpinnings 
of AATD remain unclear, and new mutations, 
including severe deficient mutations, are yet to 
be detected. A better understanding of the 
genetic factors involved in AATD-mediated 
liver disease could help in the development of 
new therapeutic strategies. This review aims to 
provide an overview of our understanding 
of AATD-mediated liver disease, from the 
clinical features to the molecular mechanisms. 
Additionally, it opens a discussion about the 
therapeutic prospects.
GENERALITY: ALPHA-1 ANTITRYPSIN 
PRODUCTION, SECRETION, AND 
ACTION 
SERPINA1 is highly polymorphic, with more than 
100 alleles identified.11 The gene is composed of 7 
exons and 6 introns located on the q arm of the 
human chromosome 14 (14q32.1). Transcription 
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of SERPINA1 results in 11 mRNA divided into 5 
mRNA products: 1.8, 1.9, 1.95, and 2.0 kb-sized 
transcripts expressed by monocytes, and a 
1.6 kb-sized transcript expressed exclusively by 
hepatocytes. They are generated by variability in 
transcription start sites and alternative splicing 
of untranslated exons according to tissues. A 
translation site beginning at exon 2 results in 
the production of 418 residues with a 24-residue 
peptide signal.12 This peptide signal promotes 
the targeting of the AAT protein towards the 
endoplasmic reticulum (ER). In this organelle, 
AAT is 3-N glycosylated and then acquires native 
form in the Golgi. AAT is composed of two ß 
sheets, nine α helices, and a reactive loop, and is 
secreted into the bloodstream. 
AAT is the most abundant serine proteinase 
inhibitor in human plasma and is mainly produced 
and secreted by hepatocytes. However, other 
cells such as neutrophils, macrophages, 
monocytes, and epithelial cells also produce AAT 
in smaller quantities. AAT plasma concentration 
varies from 0.9–2.0 g/L and according to 
the body's inflammatory regulation.13 During 
inflammation (acute phase), AAT levels increase 
rapidly by 3–4-fold. The protein inhibits a 
range of pro-inflammatory proteases, such as 
proteinase 3, cathepsin G, and NE.14 The 
mechanism of inhibition has been determined 
by crystallographic studies. Targets, such as 
NE, bind to the reactive loop of AAT, which 
constitutes a trap for the target protease, and 
cleave at a precise site causing a conformational 
transition. The amino terminal half of the reactive 
loop is inserted into the main ß-sheet, which 
acquires an extra strand. The reactive loop 
residue, located upstream of the cleavage, flips 
from the upper to the lower pole of the protein, 
carrying with it the protease trapped within a 
covalent complex. The resulting inactive AAT/
protease complex is highly stable.15 
AAT is crucial in inhibiting these molecules 
and maintaining the balance of protease/anti-
protease that are important for lung integrity. 
Consequently, AATD predisposes patients to 
lung injury. 
ALPHA-1 ANTITRYPSIN DEFICIENCY 
As previously mentioned, AATD is caused by a 
mutation in the SERPINA1 gene that predisposes 
not only to lung injury but also liver damage. 
Over 100 mutations have been described to 
date and are classified as deficient or null.16 Null 
variants are characterised by undetectable levels 
of AAT in the serum due to nonsense mutations 
or frameshifts leading to a premature stop 
codon. However, deficient variants, such as the 
well-known Z-variant, are characterised by low 
levels of circulating AAT, generally due to a point 
mutation or small deletions.16 
The two variants named ‘Z’ and ‘S’ are the most 
common. These mutants are so named because 
of their isoelectrofocussing pattern in which they 
migrate slowly compared to the wild type (WT) 
isoform referred to as M-AAT. These two variants 
are caused by point mutations (Glu342Lys 
and Glu264Val, respectively), which result in 
aberrantly folded protein.1,17 The Z variant is the 
most severe form and its mutation results in the 
aggregation of Z-AAT, resulting in greater plasma 
deficiency and potentially hepatocyte toxicity 
and liver damage. 
Z-AAT Mutant 
As previously mentioned, the Z-variant is the 
result of a lysine substitution by glutamate at 
position 342. This mutation leads to the retention 
of the Z-variant in the ER,18 where it interacts 
with chaperones such as Grp78/BiP, Grp94, 
Grp170, and calnexin, all of which have been 
shown to contribute to its ER retention (Figure 
1).19 The Z-variant is retained within the ER in both 
soluble and aggregate forms. The latter may be 
bound into the hepatocytes in inclusion bodies 
(IB) and may predispose to liver injury.20
This histopathological hallmark of the disease 
stains positively in hepatocytes with periodic 
acid–Schiff after treatment with diastase. 
The mechanism of IB formation is not clearly 
understood. It was proposed that these IB are 
a part of the ER components and could have a 
protective effect on hepatocytes.21 Moreover, 
there is heterogeneity in the distribution and size 
of IB within hepatocytes, many of which are free 
or resemble small clouds of 'dust', while others 
are huge and well-marked. This difference and 
its association with the disease outcome is yet to 
be explained.
These structures are formed by the opening of 
ß-sheet, which can accept the loop of another 
molecule to form a dimer that extends into 
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aggregates.18 Due to the retention of the Z 
mutant in the ER of hepatocytes, homozygous 
ZZ patients have approximately 85% lower 
circulating levels of AAT. The retention and 
accumulation of this mutant in the ER could 
have a gain-of-function toxic effect leading to 
hepatocyte toxicity and death, thus predisposing 
homozygotes to liver diseases.22
Other Mutant-Mediated Liver Disease 
The Z-variant is not the only AAT mutant involved 
in liver diseases. Rare variants, such as Mmalton 
(Phe51/52 del) and Siiyama (Ser53Phe), may 
cause liver disease (Table 1).23,24 An Italian study 
has reported that among subjects with severe 
AATD, 11% carried a genotype other than the 
common Z or S/Z, and 13% of this population had 
developed a chronic liver disease.27 According 
to the Spanish Register of AATD patients, 
Mmalton is the most prevalent deficient rare 
variant.28 Unfortunately, given the extreme 
rarity of such variants, their detection seems to 
be underestimated.
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Figure 1: Fate of Z-Alpha-1 antitrypsin within the endoplasmic reticulum. 
The nascent Z-AAT undergoes N-glycosylation and enters the quality control/calnexin cycle. A prolonged time of 
association of Z-AAT with members of the calnexin cycle coincides with its targeting to the degradation pathway. 
Two major pathways are involved in Z-AAT degradation: ERAD/ubiquitin-proteasome system for the soluble 
forms (left), and autophagy for the aggregate forms (right). It was shown recently that Z-aggregates undergo 
a novel clearance pathway named ERLAD. This event is under the control of the ER-phagy receptor FAM134B. 
The expression and accumulation of intracellular Z-aggregates is not associated with the induction of the UPR. 
Nevertheless, those aggregates seem to sensitise the cell to a ‘second hit’, such as HDR1 or HERP mutations (in red) 
that can induce a UPR more efficiently than observed in wild type cells. Mutations in ERAD members (in red) have 
been associated with liver disease. 
AAT: alpha-1 antitrypsin; ATF6: activating transcription factor 6; BiP: binding immunoglobulin protein; EDEM: ER 
degradation-enhancing α-mannosidase-like protein; ER: endoplasmic reticulum; ERAD: ER-associated degradation; 
ERLAD: ER-to-lysosome-associated degradation pathway; ERManl: ER α-mannosidase I; HRD1: HMG-CoA reductase 
degradation 1; IRE1: inositol-requiring enzyme 1; PERK: protein kinase RNA-like ER kinase; UDP: uridine diphosphate; 
UGGT1: UDP-glucose glycoprotein glucosyltransferase 1; UPR: unfolded protein response.            
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Similar to the Z mutant, Mmalton and 
Siiyama mutants form polymers and IB in the 
hepatocytes. However, the formative processes 
and nature of these aggregates are different 
depending on the variant. First, only the 
Z aggregates are recognised by the non-
commercial monoclonal antibody ATZ11.25 
In addition, IB resulting from the Mmalton 
variant contain calcium precipitates.26 A 
better diagnostic, molecular characterisation, 
and identification of the factors and stress 
pathways induced by these rare variants must 
be undertaken.
ALPHA-1 ANTITRYPSIN DEFICIENCY 
AND LIVER DISEASE 
In 1969, Sharp et al.29 were the first to establish 
a link between AATD paediatric homozygous ZZ 
patients and liver disease. It is now well-known 
that AATD may be associated with liver damage 
in infancy, childhood, and adolescence, as well as 
later in adult life. 
However, not all patients develop liver disease, 
and the symptoms and outcomes of the disease 
are highly variable: these include the age or 
stage of the first manifestation, as well as the 
rate of progression of the damage. Both an 
acute or chronic form of liver injury may be 
encountered. A recent review of the Organ 
Procurement and Transplantation Network 
database for liver transplantation in the USA has 
shown that there are two peak ages for severe 
AATD-associated liver disease: 0–5 and 50–65 
years of age.8 
In brief, a small subset of affected children will 
develop severe liver disease in the first decade 
of their life, others may develop and grow up 
normally, because most adolescents display 
normal liver enzyme levels30 even in the presence 
of advanced liver disease.31 
In this chapter, the authors discuss the clinical 
characteristics of the disease, such as the 
different forms and symptoms associated 
with AATD during childhood and adulthood. 
We also discuss the incidence of genetic and 
environmental factors and the heterozygous 
status in the development of liver diseases 
associated with AATD.
Liver Disease During Childhood 
The main clinical characteristic of childhood 
liver disease is usually persistent jaundice, which 
is a general hallmark of neonatal cholestasis 
observed during the first 1–2 months after birth. 
In addition to this, infants may present with 
itching, bleeding, trouble eating, and elevated 
liver enzyme levels. Although neonatal 
cholestasis disappears in 3–6 months, in severe 
cases, this cholestasis may progress to cirrhosis 
with early development of portal hypertension 
and liver failure.32 In toddlers, the liver damage 
associated with AATD may present without 
chronic liver disease or with isolated signs such as 
an accumulation of fluid in the abdominal cavity 
(ascites), splenomegaly, or hepatomegaly.
Variant Mutation site Liver disease Detection References
Z Glu342Lys Liver damage: 
fibrosis, cirrhosis, 
hepatocellular 
carcinoma
PAS-Diastase 
positive; polyclonal 
and monoclonal 
antibodies
18, 25   
Mmalton Phe51/52 Δ Risk of severe liver 
disease
PAS-Diastase positive; 
calcium precipitates 
detected by Von 
Kossa staining
23, 26
Siiyama Ser53Phe Risk of severe liver 
disease
PAS-Diastase positive 24
Table 1: Alpha-1 antitrypsin variant-mediated liver disease. 
PAS: periodic acid–Schiff.
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Much of what is known about AATD-associated 
liver disease during neonatal period and 
during childhood comes from a prospective 
study by Sveger,33 who has determined the 
frequency of liver disease. In his study, Sveger33 
screened 200,000 newborns in Sweden and 
identified 127 homozygous ZZ patients who 
were monitored until 12 and 18 years of age. 
From this group of homozygotes, 14 had 
prolonged obstructive jaundice and 9 of the 14 
had severe liver disease. The authors concluded 
that only 15% of homozygous ZZ patients had 
developed clinically significant liver disease 
in the first 4 decades of life, and <3% of those 
had progressed to life-threatening end-stage 
disease as infants.33,34 Recently, a study from the 
French paediatric cohort named DEFI-ALPHA 
has observed that in France, 18.3% paediatric 
AATD patients had a severe liver disease and 
almost half of them ended up with a liver 
transplantation.35 The lower rate of liver disease 
reported in the Swedish study might be due to the 
mode of patient recruitment. Indeed, the patients 
in the study by Sveger33 were recruited through 
neonatal screening, whereas only patients with 
known AATD were included in the French study. 
As previously mentioned, the majority of AATD 
patients are healthy or free of chronic disease by 
18 years of age. However, for some of them, this 
period of few or no signs of liver damage will end 
and severe, progressive liver disease will onset 
during their adulthood.
Liver Disease During Adulthood 
AATD adults may develop chronic hepatitis, 
cirrhosis, and HCC, and the incidence of liver 
disease increases with age.36 Liver disease is 
more common in adults than in children. Chu et 
al.8 have shown that currently more than 88% of 
patients who undergo a liver transplantation for 
AATD are adults, with the peak age range being 
50–64 years. This condition is under-recognised 
and undiagnosed during adulthood because 
biochemical and histopathologic analyses in 
homozygous ZZ adults may produce results 
similar to those for alcoholic liver disease.
In adult AATD, advanced liver fibrosis is present 
without clinical liver disease, and fibrosis on 
biopsy is detected in approximately one-third 
of AATD adults.37-39 In addition, several studies 
have reported obesity as a risk factor for liver 
disease in AATD adults.39,40 The prevalence 
of hepatic steatosis in adult AATD is higher 
than 20–30% expected for the general USA 
population and represents a secondary cause 
of hepatic steatosis similar to other genetic/
metabolic diseases. Valenti et al.41 evaluated the 
impact of the two most relevant AAT variants 
in two large cohorts of nonalcoholic fatty liver 
disease and chronic alcohol misuse. The authors 
found that the Z-variant is a major risk factor 
for cirrhosis in the context of chronic metabolic 
injury such as nonalcoholic fatty liver disease and 
chronic alcohol misuse.41 
To summarise, risk factors for adults with 
liver disease in AATD are age >50 years, 
male sex, repeated elevated liver enzymes, 
hepatitis virus infection, obesity, diabetes, and 
metabolic syndromes.39
Liver Disease and Genetic and 
Environmental Influences
As previously mentioned, only about 15% of 
homozygous ZZ patients develop clinically 
significant liver disease in their childhood. Other 
co-factors, such as hepatitis, obesity, metabolic 
syndromes, or alcohol intake,  could augment 
the risk of hepatic disease during adulthood 
but obviously not during childhood. 
Consequently, the modifiers in the infant 
form of severe and progressive liver disease 
remain unidentified. Since not all patients with 
the homozygous ZZ genotype develop end-
stage disease, it has been suggested that 
genetic and environmental factors may be 
implicated in variability of onset and disease 
severity. From a clinical point of view, AATD 
patients with neonatal cholestasis are 
likely to develop severe liver disease.35 
Other risk factors, such as male sex or 
the absence of breastfeeding, were found 
to not be associated with severe liver damage.35 
From a cellular/genetic perspective, in 2009, 
based on a candidate gene-sequencing 
strategy, Pan et al.10 demonstrated that 
differences in ER mannosidase I expression were 
associated with an earlier age-of-onset for end-
stage liver disease. However, the significance 
of this association has been challenged, as a 
replicate study in another cohort failed to 
reproduce the results.42 Recently, a study that 
focussed on the MAN1B1 gene (that encodes 
the ER mannosidase I protein) and SERPINA1 
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gene showed that no genetic polymorphisms 
in these two genes influence the onset and 
severity of liver disease in AATD during 
childhood.43 Finally, the authors’ group had 
identified two mutations, HERPUD1 R50H and 
HFE H63D, that were associated with the 
advanced liver disease component of AATD.9 
Based on this work, they have also observed 
that specific pathways, including ER-associated 
degradation pathway (ERAD) and Unfolded 
Protein Response (UPR), could be novel risk 
factors for AATD-caused liver disease (Figure 1).9 
However, these results are in line with the findings 
of a large-scale screening study for AATD.9
The AATD-associated liver disease during 
adulthood could be predominantly an age-
dependent degenerative disease. This hypothesis 
is consistent with different studies using an 
AATD mice model that showed differences in 
the activation and expression of proteins and 
molecular pathways between livers from young 
mice and older mice.44,45 These results suggest 
that different modifiers (co-factors, stress 
pathways) are involved in the infant and the 
adult form of the disease, and that their 
identification is crucial for accurate treatment 
of patients.
Alpha-1 Antitrypsin Deficiency and 
Hepatocellular Carcinoma
Although the incidence of AATD on HCC 
development is still controversial, some studies 
have pinpointed AATD as a risk factor for the 
development of the cancer.46 Based on the 
AATD mouse model,47 the livers of 79 Z-AATD 
and 18 WT mice were analysed. Liver pathology 
was seen more frequently in Z-AATD livers 
(47/79) than in WT (5/18), a development that 
was also age-related. In older Z-AATD mice (18–
24 months), livers showed malignant tumours 
(HCC and angiosarcoma) (17/50), hyperplastic 
nodules (28/50), and non-specific changes 
(33/50), whereas only 9/50 were normal.47 
Similarly, a Swedish autopsy study based on 31 
autopsied adults with severe AATD has shown 
that in the homozygous ZZ group, there were 13 
cases of cirrhosis, 5 cases of HCC, and 8 cases of 
gallstone disease.48 Consequently, AATD patients 
are at greater risk of cirrhosis and HCC, with the 
risk of HCC being higher in males. 
From a molecular perspective, a comparative 
‘omics’ approach between diseased human-
induced pluripotent stem cell-derived and WT 
hepatocytes has pinpointed specific proteins 
associated with predisposition to malignancy 
that are highly upregulated in the former.49 
More recently, another study has examined 
the contribution of DNA methylation to AATD 
adult liver disease heterogeneity, where the 
global analysis revealed significant genomic 
hypomethylation in AATD liver impacting genes 
related to liver cancer.50
Heterozygotes 
Retention of Z-AAT within hepatocytes is 
responsible for liver disease. Recently, a clear 
relationship between Z-AAT accumulation and 
fibrosis was demonstrated.39 According to that 
study, only patients carrying aggregate-forming 
AAT variants are susceptible to developing 
liver disease. Thus, it is not surprising that 
heterozygous patients, such as those with SZ 
or MZ variants, can also develop severe liver 
disease in childhood and adulthood.35,51 Hence, 
it has been suggested that heterozygosis 
increases the risk of developing liver disease. 
Interestingly, the incidence of liver disease could 
be higher in heterozygotes with the deficiency 
than in the general population, especially 
if the affected individuals have other liver 
comorbidities.5 Many patients who undergo 
liver transplantation with a diagnosis of AATD 
are actually heterozygotes who also have other 
risk factors (e.g., alcohol usage or steatosis).8,52 
Recently, two cohort studies have shown that 
that Z allele is a risk factor for cirrhosis in 
alcoholic and nonalcoholic fatty liver diseases.53 
Among patients with cirrhosis, decompensation 
of cirrhosis with ascites or encephalopathy was 
significantly more frequent in patients with MZ 
than in homozygous MM or WT allele patients.54 
The MZ genotype is a genetic risk factor for 
more advanced cirrhosis and decompensation, 
especially if the affected individuals have other 
liver comorbidities. Z heterozygous variants 
seem to be strong risk factors for the severity of 
chronic liver diseases.
Given that the MZ genotype represents 2% of 
the USA and European populations, and the 
fact that the Z allele represents a strong disease 
modifier, Z allele carriers are at higher risk. Hence, 
genotyping for the Z allele should be considered 
as the first-line test in all patients with cirrhosis. 
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Finally, further research is needed to define the 
clinical features of heterozygous Z and S carriers 
and determine whether those AAT variants 
present a clinical phenotype.53,54
In conclusion, there is a wide variation in the 
forms and severity of liver injury among AATD 
patients and, as mentioned above, very little is 
known about predispositions. This variability 
may be related to how the affected individual 
responds to the intracellular accumulation of 
Z-AAT in hepatocytes. 
Z MUTANT AND MOLECULAR 
MECHANISM: FROM DEGRADATION TO 
HEPATOCYTE TOXICITY 
Z-Variant Disposal
In the ER, Z-AAT mutant accumulates both in 
soluble and aggregate forms (Figure 1). Several 
lines of evidence suggest a dose–response 
relationship between Z-AAT intracellular 
protein accumulation and liver injury. Thus, 
the accumulation of these aggregates is the 
first event of liver injury cascade. To prevent 
this dramatic issue, hepatocytes use different 
degradation pathways to protect themselves 
from proteotoxicity. Depending on the form of 
the mutant, soluble or aggregated, different 
degradation pathways have been identified 
(Figure 1). The soluble form, which represents 
most of the intracellular forms of the Z-variant 
(>80%), interacts with several proteins involved 
in important pathways, such as quality control 
or ERAD, before finally being degraded by 
the proteasome (Figure 1). Previous work has 
shown that among all the molecules involved in 
those pathways, one molecule present in the ER, 
calnexin, is a critical point of control. Calnexin is a 
transmembrane ER chaperone that binds Z-AAT 
and targets it for degradation. For instance, it has 
been shown that inhibitors indirectly affecting 
the interaction of the Z mutant with calnexin, 
such as kifunensin (mannosidase inhibitor I and 
II) or castanospermine (glucosidase inhibitor), 
restore the secretion of this variant.55 In addition 
to calnexin, studies in human fibroblast cell lines 
from homozygous ZZ patients have shown that 
patients with liver disease have less efficient 
Z-AAT degradation than homozygous ZZ 
patients without liver disease.56 These results 
suggest that many other proteins involved in 
the disposal of the Z mutant could be critical 
in the liver damage linked to AATD. Among all 
these potential proteins, different studies have 
pinpointed the ERAD pathway, with genetic 
modification in genes encoding the proteins 
Man1B1 or Herpud1 perhaps altering susceptibility 
to liver injury by changing the efficiency of 
Z-AAT degradation.9,35 
The autophagy pathway is another degradation 
pathway activated by the cell to prevent liver 
toxicity. This is a highly conserved and important 
degradation system specialised in disposal of 
protein aggregates and large structures via the 
formation of autophagosomes. Consequently, 
autophagy could rather be involved in the 
degradation of Z mutant aggregates that are 
not capable of being eliminated by the protea 
some. It has been shown that autophagosomes 
were abundant in the hepatocytes of 
homozygous ZZ patients and that Z-AAT 
retention in the ER is associated with a marked 
autophagic response.50 Consequently, some 
studies have observed that enhancing autophagy 
may reduce hepatotoxic effect. For instance, 
weekly administration of rapamycin, a mTOR 
pathway inhibitor, in a mouse model increased 
autophagy and diminished Z-AAT aggregates 
accumulation, subsequently leading to reduction 
of liver injury.57 This is also observed using 
another autophagic drug, carbamazepine (CBZ), 
a drug that reduces the hepatic fibrosis and 
inflammatory response associated with the 
Z-AAT aggregates in a mouse model.58
Nevertheless, several questions concerning 
autophagy and AATD are still unclear and 
controversial. What activates this pathway? 
Which type of autophagy (e.g., ER-phagy, 
macroautophagy) is activated by the 
aggregates? What is the mechanism of vesicle/
autophagosome formation? Some studies 
suggest an intervention of macroautophagy in 
the clearance of luminal aggregates; this would 
imply their dislocation across the ER membrane, 
or the capture of ER portions containing them 
by autophagosomes.59 Conversely, other studies 
based on the transcription factor EB master gene 
(TFEB) that regulates the autophagy pathway 
have speculated that mechanisms independent 
of mTOR or other classical macroautophagy were 
involved in the disposal of Z-AAT aggregates.58,60 
In this case, autophagy is induced due to 
reduced intracellular calcium and inositol levels. 
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Finally, it has been recently described that an ER-
to-lysosome-associated degradation pathway 
was implicated in the degradation of Z-AAT 
aggregates.61 This pathway involves calnexin and 
the engagement of the LC3 lipidation machinery 
by the ER-resident ER-phagy receptor, FAM134B 
(Figure 1). Consequently, Z-AAT aggregate 
delivery from the ER lumen to endolysosomes 
for clearance does not require ER capture within 
autophagosomes. Rather, it relies on vesicular 
transport, where single-membrane, ER-derived, 
Z-AAT-containing vesicles release their luminal 
content within endolysosomes upon membrane-
membrane fusion events.61 
Among these two degradation pathways, ERAD/
proteasome and autophagy, it remains unclear 
whether autophagy is a specific response to the 
accumulation of Z-AAT or rather a secondary 
process that becomes more important when 
ERAD and/or the proteasome are overwhelmed. 
Based on a yeast Z-AAT expression system, 
it seems that the trigger for induction of 
autophagy by Z-AAT might be the formation of 
Z-AAT aggregates.62 Indeed, at low levels, the Z 
mutant remains soluble and is disposed by the 
ERAD/proteasome pathway. Conversely, higher 
levels of Z-AAT expression induce aggregate 
formation, thereby activating the autophagy 
pathway required for their degradation. Another 
study on Z mouse liver extracts showed that 
polyubiquitin conjugates were accumulating, 
despite normal recruitment to catalytically 
active 26S proteasomes. This suggests that a 
defect at the 26S proteasome, other than the 
compromised binding to polyubiquitin chain 
or peptidase activity, plays a role in this 
accumulation.63 It is still unknown whether this 
event reflects a lack of response to an increased 
demand for the proteasome or a response 
counteract by rapid elimination of damaged 
subunits and/or complexes.
In addition to these two major degradation 
pathways, the cell can also protect itself 
from Z-AAT aggregates by activating other 
degradation pathways. For example, in a murine 
hepatoma cell line, Z-AAT is degraded by a non-
proteasomal mechanism, which is sensitive to 
tyrosine phosphatase inhibitors.64
Even if hepatocytes use different systems 
to protect themselves from the Z-AAT 
proteotoxicity consequences, in 15% of the 
homozygous ZZ patients those degradation 
pathways are not sufficient and Z-AAT aggregates 
will trigger multiple signalling events, finally 
leading to cellular toxicity and death. 
Z Mutant and Proteotoxicity 
Although several aspects of the disease 
pathogenesis are still unclear, accumulation of 
Z-AAT aggregates can affect various intracellular 
signalling pathways leading to injury cascade, 
including apoptosis. Hence, mitochondria 
have been closely associated with the Z-AAT 
aggregates toxicity via their role in apoptosis 
induction. In a Z-AAT mouse model, 
both mitochondrial and liver injuries were 
reduced with the administration of cyclosporin 
A, an inhibitor of mitochondrial permeability 
transition.65 Recently, transcriptome and 
proteome analyses using human induced 
pluripotent stem cells derived from patients with 
Z-AAT differentiated into hepatocyte-like cells 
in comparison to patient-specific genetically 
corrected hepatocyte-like cells, have confirmed 
that Z-AAT aggregates were associated with 
disrupted mitochondrial structure.49 
Other pathways have been linked to the 
Z-variant and cell toxicity. For instance, the 
accumulation of Z-AAT aggregates triggers 
NF-κB signalling through a pathway named ‘ER 
overload response’.66 Although this response 
remains unclear, it seems that a leakage of 
calcium from the ER might have a role in its 
activation. Moreover, it has been shown that 
the kinases c-Jun N-terminal kinase 1 (JNK1), 
2 (JNK2), and c-Jun play important roles in the 
pathogenesis of the liver disease by controlling 
the degree of Z-AAT accumulation.67 Finally, 
oxidative stress was shown to contribute to liver 
damage in a murine model of Z-AAT. Higher 
levels of reactive oxygen species and a more 
oxidised cellular redox state are observed in liver 
tissue from Z-AAT mice compared to WT mice.67
Interestingly, the accumulation of intracellular 
Z aggregates is associated with multiple 
pathways, but in the absence of the induction 
of the UPR. This pathway is generally activated 
when misfolded proteins accumulate within 
the ER. Thus, UPR activation reduces the 
entry of nascent proteins into the ER and 
improves the folding and degradation of 
misfolded proteins. One hypothesis is that the 
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absence of UPR activation might be caused by 
the structure of the Z-AAT aggregates. Indeed, 
these structures are relatively well-folded, and 
they might not contain hydrophobic areas/
misfolded parts. Nevertheless, the accumulation 
of Z-AAT aggregates seems to sensitise the 
cell to a ‘second hit’ that can induce an UPR 
more efficient than that observed in WT cells 
(Figure 1).9,68
THERAPEUTIC STRATEGIES 
Currently, there is no specific treatment for AAT-
associated liver disease, other than standard 
liver supportive care, such as ursodeoxycholic 
acid.69 Generally, management of the disease 
focusses on preventing the complications of 
chronic liver disease.69 In severe cases, when 
life-threatening liver disease does develop, liver 
transplantation is performed with excellent 
success rates.69 Following liver transplantation, 
the serum AAT levels return to normal.69 To 
overcome the absence of specific treatments, 
several therapeutic strategies have been 
employed. They consist of interfering in the 
different pathways in which the Z-variant is 
involved (Table 2).
Reducing the Amount of  
Z-AAT Aggregates
Since the accumulation of the Z-variant 
aggregates into the ER can trigger liver damage, 
one of the first strategies implemented is to 
reduce this accumulation in the ER. 
For this purpose, small interfering RNA (siRNA), 
targeting mRNA encoding human AAT, have 
been developed by two biotechnology 
companies: Arrowhead Research Corporation 
and Alnylam Pharmaceuticals, Inc. In transgenic 
mice expressing the Z-variant, siRNA treatment 
reduced the accumulation of Z-AAT in 
hepatocytes, the formation of inclusion bodies, 
and liver fibrosis.70 Moreover, in non-human 
primates, 80% of AAT in the bloodstream is 
reduced following siRNA treatment. This strategy 
has been extended to humans. In June 2015, 
Phase I/II clinical trials using the siRNA named 
ALN-AAT was conducted in healthy patients 
and homozygous ZZ patients who developed 
liver damage. Although circulating AAT 
levels decreased significantly (about 75% on 
average) up to 6 months at a single dose of 
6 mg/kg, liver enzymes increased in three 
patients, indicating liver.83 The other candidate 
is the Arrowhead siRNA AAT, named ARC-AAT. 
A Phase I study, in healthy volunteers and AATD 
patients, had been launched and was terminated 
in January 2017. ARC-AAT was well-tolerated 
and induced deep and durable reduction of AAT. 
Thus, a Phase II study was recently initiated to 
determine the safety and effect on circulating 
and intrahepatic AAT levels of ARC-AAT.84,85 
Further details about and the conclusions of this 
programme are pending.
Rather than targeting mRNA, another way to 
prevent the accumulation of Z-AAT in the ER 
would be to directly correct the mutated gene 
by using a gene editing approach, such as 
CRISPR/Cas9. The CRISPR/Cas9 approach 
uses a guide RNA, which is homologous to 
that of the DNA to be excised/targeted, and a 
Cas9 enzyme, which is an endonuclease, the 
co-operation of which leads to a DNA double 
strand break at a specific location. This approach 
has already been used in a transgenic mouse 
model expressing human Z-AAT.71 A guide RNA 
specific for hSERPINA1 expressed in the liver 
has been used with the aim of disrupting the 
gene and reversing the disease phenotype. Thus, 
with this treatment, the author has shown a 
reduction in protein aggregation, hepatocellular 
proliferation, and liver fibrosis without off-target 
DNA editing.72 
Increasing the Degradation Pathway
Autophagy and the ERAD/proteasome pathway 
mainly remove the aggregate and the soluble 
Z-AAT forms, respectively. Therefore, one 
of the strategies would be to increase these 
degradation pathways. The most promising 
advances have been with autophagy enhancer 
treatments. One interesting avenue involves 
CBZ, a drug largely used for epileptic treatment, 
which has been shown to enhance both 
autophagy and proteasome pathways in AATD 
cellular and mouse models. CBZ increases 
intracellular degradation of the Z-variant and, 
in a mouse model, administration of large 
doses (>10-times the recommended dose for 
humans) reduced intrahepatic Z-AAT inclusion 
and reversed hepatic fibrosis associated with 
AATD.58 Following these encouraging results in 
2012, a Phase II clinical trial has been conducted 
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on 30 AATD patients with severe liver disease. 
This clinical trial will be finished in 2020 and 
will provide us more details on CBZ efficacy 
in humans.86 
Table 2: Therapeutic strategies for alpha-1 antitrypsin deficiency-associated liver disease. 
Name Mechanism Disease models Stage of 
development
Reference(s)
Genetic 
approaches
siRNA Targeting mRNA 
encoding human 
AAT; reducing 
the accumulation 
of AAT in 
hepatocytes and 
liver fibrosis; 
reducing the 
formation of 
inclusion bodies 
Mouse model; 
non-human 
primates
Clinical trials 70
CRISPR/Cas9 Gene editing 
approach; 
reducing protein 
aggregation, 
hepatocellular 
proliferation; and 
liver fibrosis
Mouse model Clinical trials 71, 72
Autophagic 
enhancers
Drugs: 
carbamazepine, 
rapamycin, 
fluphenazine, 
pimozide 
Gene therapy: 
transcription 
factor EB
Autophagy-
inducing agents; 
induce autophagic 
disposal of Z-AAT 
aggregates, 
decrease liver 
aggregates; 
inflammation, and 
fibrosis
Caenorhabditis 
elegans;   
mammalian cell 
lines; mouse 
model
Clinical trials for 
carbamazepine 
compounds
57, 60, 73-76
Chaperones 4-phenylbutyric 
acid;    
suberoylanilide 
hydroxamic 
acid
Histone 
deacetylase 
inhibitors; increase 
Z-AAT secretion
Mammalian cell 
lines; mouse 
model; human
Human 
randomised trial 
failed
55, 77, 78
Aggregation 
blockers
Structure-
based drugs; 
monoclonal 
antibody: 
mAb4B12
Structure-based 
drugs that target 
the hydrophobic 
pocket and the 
reactive centre 
loop of Z-AAT. 
The antibody 
interacts with 
the helix-rich 
region spanning 
helices A, C, G, 
H, and I. These 
agents reduce the 
aggregation of 
Z-AAT 
In silico  
screening; in vitro; 
mammalian cell 
lines
These agents have 
not been tested in 
animal models
79-82
AAT: alpha-1 antitrypsin; PAS: periodic acid–Schiff. 
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As observed with CBZ, another pro-autophagic 
agent, rapamycin, has been shown to be 
effective in clearing Z-AAT aggregates in cell 
lines and in mice that express the Z-variant. This 
was associated with a reduction in markers of 
hepatocellular injury, such as hepatic fibrosis.57 
Given these findings, and as these two pro-
autophagic agents do not act through the same 
molecular pathway, a combined treatment of 
CBZ (mTOR-independent) and rapamycin 
(mTOR-dependent), would be interesting to 
test. In the light of pro-autophagy and AATD, a 
drug screen based on an AATD Caenorhabditis 
elegans model has identified several other 
drugs that enhance the autophagic disposal 
of Z-AAT.73 Finally, an alternative approach 
to enhance autophagy is to use a viral vector 
that expresses the transcription factor TFEB, 
which is a master regulator of autophagy. TFEB 
localises to the lysosomal membrane, and, upon 
dephosphorylation, the factor is activated and 
transported into the nucleus where it acts as 
a transcription factor. TFEB has been shown 
to modulate lysosomal clearance74 and induce 
autophagy.75 The effect of TFEB gene transfer 
on the induction of autophagy and lysosomal 
biogenesis has already shown efficacy in 
lysosomal storage diseases.76 Concerning AATD, 
it has been shown in a mouse model that gene 
transfer of TFEB reduced the accumulation of 
Z-AAT, liver apoptosis, and fibrosis.60 
Improve the Folding/Inhibit 
Polymerisation 
Another strategy to reduce the accumulation of 
Z-AAT is to improve its folding and/or increase 
its secretion by, for instance, using chemical 
chaperones that can facilitate mutant protein 
folding and trafficking. Among these chemical 
chaperones, suberoylanilide hydroxamic and 
4-phenylbutyrate, two histone deacetylase 
inhibitors, have been shown to increase the 
secretion of Z-AAT in cellular and in vivo 
models.55,77 However, a human randomised 
trial failed to demonstrate the efficacy of 
4-phenylbutyrate.78 
Another avenue of treatment could be a 
‘structure-based’ drug development.79 A better 
knowledge of polymer formation has permitted 
drug discovery. Polymers have a hydrophobic 
pocket, which accepts an exogenous reactive 
loop peptide. Mutation in this hydrophobic 
pocket has been initially shown to reduce Z-AAT 
aggregate formation and increase the secretion 
of Z-AAT using a Xenopus oocyte expression 
system.80 Furthermore, small-molecule drugs 
that target the hydrophobic pocket and 
peptides that target the reactive centre loop 
of AAT have been tested and were found to 
prevent Z-AAT aggregation.81 Nevertheless, 
some of these drugs and peptides increase 
intracellular degradation rather than Z-AAT 
secretion, or improve the rate of secretion but 
lead to more Z-AAT intracellular accumulation. 
Moreover, these peptides have not been tested in 
animal models. 
Recently, monoclonal antibodies such as 
mAb4B12 were shown to reduce the accumulation 
of Z-AAT polymers in vitro but failed to prevent 
Z aggregation and increased its secretion 
in cellulo.82
Other Treatments
As mentioned previously, oxidative stress has been 
associated with AATD liver damage. Antioxidant 
therapy, such as with Vitamins A, C, and E, and 
N-acetylcysteine could be interesting to test and 
evaluate.
With the recent advances in our knowledge of 
gene editing, a cell transplantation therapy for 
AATD could be also considered. Ding et al.87 
demonstrated that WT donor hepatocytes could 
almost completely repopulate the liver of the 
AATD mouse model. In addition, a biallelic 
correction of the Z-AAT point mutation 
(Glu342Lys) in human iPSC (from a homozygous 
ZZ patient) had been achieved by a combination 
of zinc finger nucleases and piggyBac 
technology.51 Subsequently, these cells were 
engrafted into the liver of a transgenic mouse 
model, which were able to colonise the liver in 
vivo and display functional activities. This exciting 
strategy could protect against COPD and liver 
damage associated with AATD. 
CONCLUSION 
AATD is a genetic disorder associated with an 
increased risk of liver disease in children and 
adults. AATD is caused by mutations in the 
SERPINA1 gene encoding the AAT protein. Among 
mutations responsible for AATD, Z mutant is 
the most severe and common deficient variant. 
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